Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,109,608
  • Shares Outstanding, K 260,467
  • Annual Sales, $ 4,163 M
  • Annual Income, $ 1,177 M
  • 60-Month Beta 0.79
  • Price/Sales 13.14
  • Price/Cash Flow 44.08
  • Price/Book 7.28
Trade VRTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 2.01
  • Number of Estimates 8
  • High Estimate 2.44
  • Low Estimate 1.84
  • Prior Year 0.97
  • Growth Rate Est. (year over year) +107.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
208.23 +1.61%
on 10/22/20
280.99 -24.70%
on 10/13/20
-52.24 (-19.80%)
since 09/23/20
3-Month
208.23 +1.61%
on 10/22/20
285.57 -25.91%
on 07/27/20
-72.88 (-25.62%)
since 07/23/20
52-Week
189.35 +11.74%
on 10/24/19
306.08 -30.87%
on 07/07/20
+21.07 (+11.06%)
since 10/23/19

Most Recent Stories

More News
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.

GILD : 60.79 (+0.20%)
IMMU : 87.86 (+0.05%)
VRTX : 211.58 (+0.71%)
HZNP : 77.44 (+1.81%)
CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study

CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.

VRTX : 211.58 (+0.71%)
CRSP : 92.65 (+2.76%)
ALNA : 1.3900 (-2.11%)
ETON : 7.64 (-3.78%)
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VRTX : 211.58 (+0.71%)
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

BIIB : 265.00 (-0.67%)
REGN : 579.81 (+0.71%)
GILD : 60.79 (+0.20%)
VRTX : 211.58 (+0.71%)
BSTC : 88.16 (+0.05%)
CRSP : 92.65 (+2.76%)
In Pursuit of the Elusive Drug -- the Billion-Dollar Blockbuster

, /PRNewswire/ -- Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired — all in search of the next blockbuster drug. While the discovery of a blockbuster...

KBLM : 11.04 (+36.30%)
KBLMR : 0.3600 (+0.11%)
KBLMW : 0.2250 (+6.89%)
ALXN : 121.61 (+1.62%)
GILD : 60.79 (+0.20%)
LLY : 142.38 (+0.52%)
VRTX : 211.58 (+0.71%)
AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review

AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.

AZN : 52.00 (+0.08%)
RHHBY : 41.0300 (+0.20%)
MRK : 79.83 (+0.78%)
VRTX : 211.58 (+0.71%)
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity

Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity

AMED : 251.11 (+0.92%)
CVS : 60.25 (+1.29%)
VRTX : 211.58 (+0.71%)
NSP : 76.79 (+0.10%)
MTH : 100.26 (+4.07%)
Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co

Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co

MMM : 169.80 (-0.53%)
PKI : 124.45 (-0.60%)
SWK : 178.01 (unch)
VRTX : 211.58 (+0.71%)
AJG : 107.92 (+0.15%)
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

VRTX : 211.58 (+0.71%)
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure

The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.

JNJ : 145.24 (+0.11%)
AZN : 52.00 (+0.08%)
LLY : 142.38 (+0.52%)
VRTX : 211.58 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 215.83
1st Resistance Point 213.70
Last Price 211.58
1st Support Level 209.26
2nd Support Level 206.95

See More

52-Week High 306.08
Fibonacci 61.8% 261.49
Fibonacci 50% 247.71
Fibonacci 38.2% 233.94
Last Price 211.58
52-Week Low 189.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar